ID 633 - Kwas eikozapentaenowy

PL: Kwas eikozapentaenowy
EN: Eicosapentaenoic acid (EPA)
Pdf: eicosapentaenoic acid

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituent that is the subject of the health claims is eicosapentaenoic acid (EPA).
EPA is a 20-carbon fatty acid with 5 double bonds of the omega 3 series (omega-3 long-chain polyunsaturated fatty acid). It is a well recognised nutrient naturally present in foods from animal sources, especially oily fish, or used, generally in the form of triglycerides, for addition to foods or food supplements. EPA is measurable in foods by established methods.
The Panel considers that the food constituent, eicosapentaenoic acid (EPA), which is the subject of the health claims is sufficiently characterised.

2.1. Poprawa nastroju (ID 633)

The claimed effect is “mood, emotional balance”. The Panel assumes that the target population is the general population.
In the context of the proposed wording and clarification provided by Member States, the Panel assumes that the claimed effect refers to mood, which is a well defined psychological construct and can be measured by validated tests.
The Panel considers that enhancement of mood might be a beneficial physiological effect.

3.1. Poprawa nastroju (ID 633)

Fifteen references were provided to substantiate the claimed effect, including two systematic reviews, five narrative reviews and eight human studies.
The Panel notes that six references provided to substantiate the claimed effect of EPA reported results with mixtures of fatty acids, especially DHA and EPA, and not with EPA alone. The Panel considers that no conclusions can be drawn from studies on a fixed combination for the substantiation of the claim on EPA alone.
The Panel notes that nine references provided to substantiate the claimed effect addressed therapeutic use of EPA in the treatment of patients suffering from psychiatric or neurological disorders (depression, schizophrenia, Huntington‟s disease, borderline personality disorder). The Panel considers that the evidence provided does not establish that patients suffering from psychiatric or neurological disorders are representative of the general population with regard to mood, and that it is not possible to use the results of these studies to draw conclusions on the effects of EPA consumption in the general population.
The Panel concludes that a cause and effect relationship has not been established between the consumption of EPA and enhancement of mood.

Warunki i możliwe ograniczenia stosowania oświadczenia

1-2 gram EPA/day